MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Danaher Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

199.98 -2.4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

199.7

Max

204.69

Pagrindiniai rodikliai

By Trading Economics

Pajamos

268M

1.1B

Pardavimai

738M

6.5B

P/E

Sektoriaus vid.

38.752

63.778

Pelnas, tenkantis vienai akcijai

2.14

Dividendų pajamingumas

0.62

Pelno marža

16.611

Darbuotojai

61,000

EBITDA

-230M

1.4B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+31.35% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.62%

2.39%

Kitas uždarbis

2025-04-22

Kitas dividendų mokėjimo data

2025-04-25

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-16B

147B

Ankstesnė atidarymo kaina

202.38

Ankstesnė uždarymo kaina

199.98

Naujienos nuotaikos

By Acuity

25%

75%

62 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Danaher Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-05 12:54; UTC

Uždarbis

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

2025-01-29 11:44; UTC

Uždarbis

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

2024-10-22 10:35; UTC

Uždarbis

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

2024-07-23 10:55; UTC

Uždarbis

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

2025-01-29 15:25; UTC

Rinkos pokalbiai
Uždarbis

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

2025-01-29 13:56; UTC

Svarbiausios naujienos
Uždarbis

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

2025-01-29 11:08; UTC

Uždarbis

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

2025-01-29 11:07; UTC

Uždarbis

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

2025-01-29 11:07; UTC

Uždarbis

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

2025-01-29 11:02; UTC

Uždarbis

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

2025-01-29 11:01; UTC

Uždarbis

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

2025-01-29 11:01; UTC

Uždarbis

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

2025-01-29 11:00; UTC

Uždarbis

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

2025-01-29 11:00; UTC

Uždarbis

Danaher 4Q Cont Ops EPS $1.49 >DHR

2025-01-29 11:00; UTC

Uždarbis

Danaher 4Q Net $1.09B >DHR

2025-01-29 11:00; UTC

Uždarbis

Danaher 4Q EPS $1.49 >DHR

2025-01-29 11:00; UTC

Uždarbis

Danaher 4Q Adj EPS $2.14 >DHR

2025-01-29 11:00; UTC

Uždarbis

Danaher 4Q Sales $6.5B >DHR

2024-10-22 10:02; UTC

Uždarbis

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

2024-10-22 10:02; UTC

Uždarbis

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

2024-10-22 10:01; UTC

Uždarbis

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

2024-10-22 10:00; UTC

Uždarbis

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

2024-10-22 10:00; UTC

Uždarbis

Danaher 3Q Sales $5.8B >DHR

2024-10-22 10:00; UTC

Uždarbis

Danaher 3Q EPS $1.12 >DHR

2024-10-22 10:00; UTC

Uždarbis

Danaher 3Q Adj EPS $1.71 >DHR

2024-10-22 10:00; UTC

Uždarbis

Danaher 3Q Net $818M >DHR

2024-10-22 10:00; UTC

Uždarbis

Danaher 3Q Cont Ops EPS $1.12 >DHR

2024-07-23 12:39; UTC

Svarbiausios naujienos
Uždarbis

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

2024-07-23 10:05; UTC

Uždarbis

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

2024-07-23 10:05; UTC

Uždarbis

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Akcijų palyginimas

Kainos pokytis

Danaher Corp Prognozė

Kainos tikslas

By TipRanks

31.35% į viršų

12 mėnesių prognozė

Vidutinis 263.21 USD  31.35%

Aukščiausias 300 USD

Žemiausias 240 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Danaher Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

13

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

199.15 / 210.53Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

62 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.